Author Correction: Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

Affiliations

• ¹ Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. wadden@pennmedicine.upenn.edu.
• ² Johns Hopkins School of Nursing, Baltimore, MD, USA.
• ³ Division of Endocrinology and Metabolism, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
• ⁴ Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
• ⁵ Department of Epidemiology and Prevention, Wake Forest School of Medicine, Winston-Salem, NC, USA.
• ⁶ Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Department of Pediatrics, Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.
• ⁷ Vanderbilt Weight Loss Clinics, Vanderbilt University Medical Center, Nashville, TN, USA.
• ⁸ Obesity Group, Department of Endocrinology, Universidade de São Paulo, São Paulo, Brazil.
• ⁹ Eli Lilly and Company, Indianapolis, IN, USA.